Stone Ridge Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Stone Ridge Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-13,700	Closed	-$4.73M	–	1303
2018 Q2	$4.73M	Hold	13,700	–	–	0.27%	68
2018 Q1	$4.72M	Buy	+13,700	New	+$4.77M	0.28%	53
2016 Q2	–	Sell	-700	Closed	-$252K	–	42
2016 Q1	$252K	Hold	700	–	–	1.53%	25
2015 Q4	$380K	Hold	700	–	–	1.29%	11
2015 Q3	$326K	Hold	700	–	–	1.29%	16
2015 Q2	$357K	Hold	700	–	–	0.83%	25
2015 Q1	$316K	Hold	700	–	–	0.79%	28
2014 Q4	$287K	Buy	+700	New	+$275K	0.6%	39

Other funds holding REGN

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Stone Ridge Asset Management's REGN Position: Q3 2018 in Review

Stone Ridge Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2018, closing a stake of 13,700 shares — an estimated $4.73M sold.

Stone Ridge Asset Management first reported a position in REGN in Q4 2014 and held it in 8 quarters. The position peaked at $4.73M in Q2 2018. 644 funds tracked by Wall St. Rank hold REGN as of Q3 2018.

Stone Ridge Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
Stone Ridge Asset Management sold 13,700 Regeneron Pharmaceuticals shares in Q3 2018, an estimated $4.73M.
Stone Ridge Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and held it in 8 quarters.
Stone Ridge Asset Management's Regeneron Pharmaceuticals position peaked at $4.73M in Q2 2018.
644 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2018.

Based on Stone Ridge Asset Management's 13F filing for Q3 2018, filed 6 Nov 2018.